Evolus (EOLS) Gains from Investment Securities (2018 - 2026)
Evolus' (EOLS) quarterly Gains from Investment Securities came in at -$14000.0 in Q1 2026, down 100.65% YoY from $2.2 million in Q1 2025, and up 99.69% on a QoQ basis from -$4.5 million in Q4 2025.
Evolus (EOLS) Gains from Investment Securities (2018 - 2026) Analysis & Trends
Evolus (EOLS) has 9 years of Gains from Investment Securities data on file, last reported at -$14000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 100.65% year-over-year to -$14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.5 million (down 210.29% YoY) and the FY2025 annual result came in at -$6.4 million, down 188.92% from the prior year.
- Gains from Investment Securities climbed to -$14000.0 in Q1 2026, from -$4.5 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.4 million in Q3 2024 to a low of -$4.5 million in Q4 2025.
- A 5-year average of $634882.4 and a median of $1.6 million in 2024 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 278.86% — and 2025, when it slumped 388.24%.
- Tracing EOLS's Gains from Investment Securities over 5 years: stood at $1.8 million in 2022, then tumbled by 148.37% to -$875000.0 in 2023, then surged by 278.86% to $1.6 million in 2024, then tumbled by 388.24% to -$4.5 million in 2025, then soared by 99.69% to -$14000.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$14000.0 (Q1 2026), -$4.5 million (Q4 2025), and -$107000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Mn |
| Jun 30, 2026 | 1.25 Mn |
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | -4.51 Mn |
| Dec 31, 2025 | -4.51 Mn |
| Sep 30, 2025 | -107,000.00 |
| Sep 30, 2025 | -107,000.00 |
| Jun 30, 2025 | -3.91 Mn |
| Jun 30, 2025 | -3.91 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Mar 31, 2024 | 1.58 Mn |